ReviewDrugs2024
The Pharmacological Landscape for Fatty Change of the Pancreas.
Review in Drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Effects of Lifestyle Modification on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis.Current obesity reports · 2026Pooled it
- Burden of Intrapancreatic Fat Deposition in Type 2 Diabetes and the Role of Obesity: A Systematic Review and Meta-Analysis.Current obesity reports · 2026Pooled it
- The Effects of Metabolic Bariatric Surgery on Intra-pancreatic Fat Deposition and Total Pancreas Volume: a Systematic Review and Meta-analysis.Obesity surgery · 2025Pooled it
- Conceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus.Nature reviews. Gastroenterology & hepatology · 2026Review
- Fatty Pancreas: Its Potential as a Risk Factor for Pancreatic Cancer and Clinical Implications.Cancers · 2025Review
- Association between intra-pancreatic fat deposition and diseases of the exocrine pancreas: A narrative review.World journal of gastroenterology · 2025Review
- Intra-Pancreatic Fat Deposition and Pancreatitis: Insights from the COSMOS Program.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Relationship of high-density lipoprotein subfractions and apolipoprotein A-I with fat in the pancreas.Diabetes, obesity & metabolism · 2025Article
- The moderating effect of cardiometabolic factors on the association between hepatic and intrapancreatic fat.Obesity (Silver Spring, Md.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The quest for medications to reduce intra-pancreatic fat deposition is now quarter a century old. While no specific medication has been approved for the treatment of fatty change of the pancreas, drug repurposing shows promise in reducing the burden of the most common disorder of the pancreas. This leading article outlines the 12 classes of medications that have been investigated to date with a view to reducing intra-pancreatic fat deposition. Information is presented hierarchically-from preclinical studies to retrospective findings in humans to prospective interventional studies to randomised controlled trials. This lays the grounds for shepherding the most propitious drugs into medical practice through well-designed basic science studies and adequately powered randomised controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.